---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-26-010656"
form_type: "8-K/A"
ticker: "ROIV"
cik: "0001635088"
company_name: "Roivant Sciences Ltd."
filed_at: "2026-03-23T23:59:59+00:00"
generated_at: "2026-05-15T09:22:17.600892+00:00"
event_type: "litigation"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Roivant subsidiary Genevant settles LNP patent litigation with Moderna; includes license and payments

## Summary
- Settlement resolves all US and international patent infringement litigation between Genevant/Arbutus and Moderna over LNP technology in COVID-19 and other mRNA vaccines.
- Moderna receives broad license to Genevant/Arbutus patent rights for defined Moderna Licensed Products, including SPIKEVAX, mNEXSPIKE, mRESVIA, and certain other mRNA vaccines.
- Moderna will make a noncontingent lump-sum payment (amount redacted) and a contingent payment tied to the outcome of Moderna's appeal on the §1498 government-contractor defense.
- Parties stipulate to dismissal of US and ex-US litigation with prejudice; Moderna retains right to appeal only on the §1498 Disputed Matter.
- Moderna agrees not to challenge validity/enforceability of specified patents owned by Genevant/Arbutus.

## SEC filing metadata
- accession: 0001140361-26-010656
- form_type: 8-K/A
- ticker: ROIV
- cik: 0001635088
- company_name: Roivant Sciences Ltd.
- filed_at: 2026-03-23T23:59:59+00:00
- event_type: litigation
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1635088/000114036126010656/0001140361-26-010656-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1635088/000114036126010656/ef20068452_8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-26-010656
- JSON: https://secwatch.observer/filing/0001140361-26-010656.json
- Plain text: https://secwatch.observer/filing/0001140361-26-010656.txt

## Source-grounded claims
- claim_id: 40d7e8acc138e510c070e5758de838bfde1a59d3
  claim: Roivant Sciences Ltd. entered into Settlement Agreement with Moderna, Inc. and ModernaTx, Inc. (together, "Moderna") (effective 2026-03-03).
  evidence_excerpt: on March 3, 2026, Genevant, Arbutus and, solely for certain purposes, GSL, entered into a Settlement Agreement with Moderna to resolve all patent infringement litigation between Genevant/Arbutus and Moderna pending in the U.S. and internationally relating to Moderna's use of Genevant/Arbutus’ lipid nanoparticle delivery technology in its vaccines.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1635088/000114036126010656/0001140361-26-010656-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.